The biotech company has only one drug, Oxbryta, on the market, to treat sickle cell disease. Its shares were up Monday after falling on Friday.
Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results